Apolipoprotein M in patients with chronic kidney disease

Sørensen, Ida Maria Hjelm; Bertelsen, Marianne; Freese, Ellen; Lindhard, Kristine; Ullum, Henrik; Feldt‐Rasmussen, Bo; Nielsen, Lars Bo; Christoffersen, Christina; Bro, Susanne

doi:10.1016/j.atherosclerosis.2018.06.815

Cited by 16 publications

(15 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surprisingly, the apoM levels were higher in patients with nephropathy and T2D. A study conducted in patients with chronic kidney disease (CKD), of whom 30% also suffered from T2D, showed a reduction in plasma apoM levels with severity of CKD in a cohort of more than 400 patients and 35 controls (32). In another study, HDL was isolated from 20 controls and patients with CKD (33).…”

Section: Can Apom/s1p Contribute To the Diagnosis Of Diabetic Nephropathy (Dn)?mentioning

confidence: 99%

Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?

Christoffersen

2021

Front. Endocrinol.

Self Cite

View full text Add to dashboard Cite

Apolipoprotein M (apoM) is a member of the lipocalin superfamily and an important carrier of the small bioactive lipid sphingosine-1-phosphate (S1P). The apoM/S1P complex is attached to all lipoproteins, but exhibits a significant preference for high-density lipoproteins. Although apoM, S1P, and the apoM/S1P complex have been discovered more than a decade earlier, the overall function of the apoM/S1P complex remains controversial. Evidence suggests that the complex plays a role in inflammation and cholesterol metabolism and is important for maintaining a healthy endothelial barrier, regulating the turnover of triglycerides from lipoproteins, and reducing cholesterol accumulation in vessel walls. Recent studies have also addressed the role of apoM and S1P in the development of diabetes and obesity. However, limited evidence is available, and the data published so far deviates. This review discusses the specific elements indicative of the protective or harmful effects of apoM, S1P, and the apoM/S1P complex on type 2 diabetes development. Since drugs targeting the S1P system and its receptors are available and could be potentially used for treating diabetes, this research topic is a pertinent one.

show abstract

Section: Can Apom/s1p Contribute To the Diagnosis Of Diabetic Nephropathy (Dn)?mentioning

confidence: 99%

Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?

Christoffersen

2021

Front. Endocrinol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Injection of recombinant ApoM-Fc reduced age-related renal fibrosis by stimulating endothelial S1PR1 signaling [ 71 ]. Plasma apoM levels are depressed in CKD patients, but HDL-S1P content is increased [ 72 , 73 ]. Cultured mesangial cells as well as tubular epithelial cells (TEC) exposed to oxidized HDL showed increased ROS and stimulated production of pro-inflammatory factors via CD36 with activated MAPK and NF-κB pathways [ 74 , 75 ].…”

Section: Hdl Modulates Renal Parenchymal Cells and Functionmentioning

confidence: 99%

High-Density Lipoproteins in Kidney Disease

Kon

Yang

Smith

et al. 2021

IJMS

View full text Add to dashboard Cite

Decades of epidemiological studies have established the strong inverse relationship between high-density lipoprotein (HDL)-cholesterol concentration and cardiovascular disease. Recent evidence suggests that HDL particle functions, including anti-inflammatory and antioxidant functions, and cholesterol efflux capacity may be more strongly associated with cardiovascular disease protection than HDL cholesterol concentration. These HDL functions are also relevant in non-cardiovascular diseases, including acute and chronic kidney disease. This review examines our current understanding of the kidneys’ role in HDL metabolism and homeostasis, and the effect of kidney disease on HDL composition and functionality. Additionally, the roles of HDL particles, proteins, and small RNA cargo on kidney cell function and on the development and progression of both acute and chronic kidney disease are examined. The effect of HDL protein modification by reactive dicarbonyls, including malondialdehyde and isolevuglandin, which form adducts with apolipoprotein A-I and impair proper HDL function in kidney disease, is also explored. Finally, the potential to develop targeted therapies that increase HDL concentration or functionality to improve acute or chronic kidney disease outcomes is discussed.

show abstract

“…The present study was a cross-sectional analysis of baseline data from the CPH CKD Cohort Study, which is a single centre, prospective, observational study examining risk factors for progression of cardiovascular disease and advanced imaging methods for early detection of cardiovascular disease in a cohort of individuals aged 30-75 years with any diagnosis of CKD stages 1-5. This paper describes a novel cohort inspired by and based upon experience from a smaller, less detailed cohort [13].…”

Section: Study Populationmentioning

confidence: 99%

“…A fasting blood sample and a 24-h urine sample were obtained. Plasma analytes were assessed as described [13].…”

Section: Study Populationmentioning

confidence: 99%

“…Cardiovascular disease was defined as a composite of prevalent coronary artery disease, a history of previous cerebrovascular infarction, carotid endarterectomy or stenting and/or peripheral artery disease. Detailed definitions of coronary artery disease and peripheral arterial disease have been previously described [13]. Some participants had more than one cardiovascular diagnosis.…”

Section: Study Populationmentioning

confidence: 99%

See 1 more Smart Citation

Regional distribution and severity of arterial calcification in patients with chronic kidney disease stages 1–5: a cross-sectional study of the Copenhagen chronic kidney disease cohort

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Patients with chronic kidney disease (CKD) and arterial calcification are considered at increased risk of adverse cardiovascular outcomes. However, the optimal site for measurement of arterial calcification has not been determined. The primary aim of this study was to examine the pattern of arterial calcification in different stages of CKD. Methods This was an observational, cross-sectional study that included 580 individuals with CKD stages 1–5 (no dialysis) from the Copenhagen CKD Cohort. Calcification of the carotid, coronary and iliac arteries, thoracic and abdominal aorta was assessed using non-contrast multidetector computed tomography scans and quantified according to the Agatston method. Based on the distribution of Agatston scores in the selected arterial region, the subjects were divided into calcium score categories of 0 (no calcification), 1–100, 101–400 and > 400. Results Participants with CKD stages 3–5 had the highest prevalence of calcification and the highest frequency of calcium scores > 400 in all arterial sites. Calcification in at least one arterial site was present in > 90% of patients with CKD stage 3. In all five CKD stages prevalence of calcification was greatest in both the thoracic and abdominal aorta, and in the iliac arteries. These arterial sites also showed the highest calcium scores. High calcium scores (> 400) in all five arterial regions were independently associated with prevalent cardiovascular disease. In multivariable analyses, after adjusting for cardiovascular risk factors, declining creatinine clearance was associated with increasing calcification of the coronary arteries (p = 0.012) and the thoracic aorta (p = 0.037) only. Conclusions Arterial calcification is highly prevalent throughout all five CKD stages and is most prominent in both the thoracic and abdominal aorta, and in the iliac arteries. Follow-up studies are needed to explore the potential of extracardiac calcification sites in prediction of cardiovascular events in the CKD population.

show abstract

Apolipoprotein M in patients with chronic kidney disease

Cited by 16 publications

References 46 publications

Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?

Apolipoprotein M—A Marker or an Active Player in Type II Diabetes?

High-Density Lipoproteins in Kidney Disease

Regional distribution and severity of arterial calcification in patients with chronic kidney disease stages 1–5: a cross-sectional study of the Copenhagen chronic kidney disease cohort

Contact Info

Product

Resources

About